ClinicalTrials.gg
CompletedNCT05127421Updated Aug 15, 2024Results posted

Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement

A Phase 2 interventional study of Ruxolitinib cream and Vehicle in Atopic Dermatitis, sponsored by Incyte Corporation. Completed at 1 site in United States. Open to participants aged 12 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-08-15.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
12 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing ruxolitinib in Dermatitis, Atopic — 2 open to participants now, 3 under way, 1 of them phase 3. ruxolitinib · Dermatitis, Atopic.

Enrollment
8th of 15
77 · median 77
Started
2021
with 3 others
Phase 2
3 of 15
none open now
Registered
9th of 15
by date
Lead sponsor
13 of 15
Incyte Corporation

Among the 15 studies testing ruxolitinib in Dermatitis, Atopic, this one is the 8th largest by enrollment, is one of 4 that started in 2021, is one of 3 in phase 2, and was the 9th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 15 studies testing ruxolitinib in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing ruxolitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This is a randomized, double blind, vehicle controlled Phase 2 study with a 4-week open label extension in adolescent and adult participants with atopic dermatitis and head and/or neck involvement. It is intended to compare the efficacy and safety of ruxolitinib cream 1.5% BID versus vehicle cream, then further evaluate ruxolitinib cream as maintenance during the open label extension period.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • atopic dermatitis
  • adolescent
  • adults
  • in-home
  • telemedicine
04

Who can participate

Ages eligible
12 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with diagnosis of AD for at least 6 months.
  • Participants with an overall and a face and/or neck IGA score of 2 or 3 at screening and baseline.
  • Participants with AD affecting the following at screening and baseline:

    1. ≥ 0.5% of the total BSA on the face and/or neck
    2. Up to a total of 20% BSA (face and/or neck plus other body areas)
  • Willingness to avoid pregnancy or fathering children based on the criteria outlined in the protocol.
  • Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  • Participants who have an unstable course of AD (spontaneously improving or rapidly deteriorating) as determined by the investigator over the previous 4 weeks prior to baseline.
  • Participants with concurrent conditions and history of other diseases such as ; chronic or acute infection requiring systemic treatments; active acute skin infection; other concomitant skin conditions that may interfere with the evaluation of AD or compromise participant safety; other types of eczema; chronic asthma requiring high dose of inhaled .
  • Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
  • Previous treatment with systemic or topical JAK inhibitors (eg, ruxolitinib, tofacitinib, baricitinib, filgotinib, lestaurtinib, pacritinib).
  • Participants who are pregnant (or who are considering pregnancy) or lactating.
  • Laboratory values outside of the protocol -defined criteria
  • Further exclusion criteria apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    Double-blind Period: vehicle cream or Ruxolitinib cream 1.5% BID

    Participants will be treated with ruxolitinib cream 1.5% or vehicle cream twice a day (BID) in a double-blind fashion.

    Drug: Ruxolitinib cream · Drug: Vehicle

  • Experimental
    Open Label Extension: Ruxolitiib cream 1.5%

    Patients will be treated with Ruxoltinib cream 1.5% twice per day (BID) during the open label extension period. Participants who complete the double-blind period will continue into this open-label extension period for an additional 4 weeks of treatment.

    Drug: Ruxolitinib cream

Interventions

  • Ruxolitinib cream 1.5% applied twice a day (BID)"

  • DrugVehicle

    Vehicle cream applied twice a day (BID) to affected areas

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieve a ≥75% Improvement in the Eczema Area and Severity Index Score (EASI75) of the Head and Neck Region at Week 4

    The EASI scoring system examines 4 areas of the body (head/neck, trunk, upper limbs, and lower limbs) and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72; the severity strata are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. Specifically for the head and neck region, the EASI score ranges from 0 to 7.2 An EASI75 responder was defined as a participant achieving a 75% or greater improvement from Baseline in the EASI score for the head and neck.

    Time frame: Baseline; Week 4

Secondary outcomes

  1. Percentage of Participants Who Achieve an EASI75 of the Head and Neck Region at Weeks 2 and 8

    The EASI scoring system examines 4 areas of the body (head/neck, trunk, upper limbs, and lower limbs) and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72; the severity strata are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. Specifically for the head and neck region, the EASI score ranges from 0 to 7.2 An EASI75 responder was defined as a participant achieving a 75% or greater improvement from Baseline in the EASI score for the head and neck.

    Time frame: Baseline; Weeks 2 and 8

  2. Percentage of Participants Who Achieve an Overall EASI75 at Weeks 2, 4, and 8

    The EASI scoring system examines 4 areas of the body (head/neck, trunk, upper limbs, and lower limbs) and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72; the severity strata are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI75 responder was defined as a participant achieving 75% or greater improvement from Baseline in EASI score.

    Time frame: Baseline; Weeks 2, 4, and 8

  3. Double-Blind Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

    A TEAE was defined as any adverse event (AE) either reported for the first time or the worsening of a pre-existing event after the first application of the study drug. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug.

    Time frame: up to approximately 4 weeks plus 30 days

  4. Open-Label Period: Number of Participants With Any TEAE

    A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of the study drug. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug.

    Time frame: from first dose date in Open-Label Period (start of Week 5) until last follow-up visit (up to approximately 4 weeks plus 30 days)

  5. Double-Blind Period: Number of Participants With Any Grade 3 or Higher TEAE

    A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of the study drug. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. The severity of AEs was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (Grades 1 to 5). Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL). Grade 3: severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4: life-threatening consequences; urgent intervention indicated. Grade 5: death related to AE.

    Time frame: up to approximately 4 weeks plus 30 days

  6. Open-Label Period: Number of Participants With Any Grade 3 or Higher TEAE

    A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of the study drug. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug.

    Time frame: from first dose date in Open-Label Period (start of Week 5) until last follow-up visit (up to approximately 4 weeks plus 30 days)

07

Results

Posted Aug 15, 2024

Participant flow

4-Week Double-Blind Period
Participant flow — 4-Week Double-Blind Period
MilestoneDouble-Blind Period: Vehicle Cream BIDDouble-Blind Period: Ruxolitinib Cream 1.5% BIDOpen-Label Period: Vehicle Cream to Ruxolitinib Cream 1.5% BIDOpen-Label Period: Ruxolitinib Cream 1.5% BID
Started235400
Completed184800
Not completed5600
Withdrew: Lost to follow-up1000
Withdrew: Physician decision1000
Withdrew: Withdrawal by subject3100
Withdrew: Withdrawn by sponsor0400
Withdrew: Withdrawn due to e-diary compliance0100
4-Week Open-Label Period
Participant flow — 4-Week Open-Label Period
MilestoneDouble-Blind Period: Vehicle Cream BIDDouble-Blind Period: Ruxolitinib Cream 1.5% BIDOpen-Label Period: Vehicle Cream to Ruxolitinib Cream 1.5% BIDOpen-Label Period: Ruxolitinib Cream 1.5% BID
Started001747
Completed001644
Not completed0013
Withdrew: Lost to follow-up0001
Withdrew: Withdrawal by subject0011
Withdrew: Withdrawn by sponsor0001

Outcome measures

PrimaryPercentage of Participants Who Achieve a ≥75% Improvement in the Eczema Area and Severity Index Score (EASI75) of the Head and Neck Region at Week 4

The EASI scoring system examines 4 areas of the body (head/neck, trunk, upper limbs, and lower limbs) and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72; the severity strata are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. Specifically for the head and neck region, the EASI score ranges from 0 to 7.2 An EASI75 responder was defined as a participant achieving a 75% or greater improvement from Baseline in the EASI score for the head and neck.

Time frame:
Baseline; Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve a ≥75% Improvement in the Eczema Area and Severity Index Score (EASI75) of the Head and Neck Region at Week 4
percentage of participantsDouble-Blind Period: Vehicle Cream BIDDouble-Blind Period: Ruxolitinib Cream 1.5% BID
Percentage of Participants Who Achieve a ≥75% Improvement in the Eczema Area and Severity Index Score (EASI75) of the Head and Neck Region at Week 417.4 (5.0 to 38.8)37.0 (24.3 to 51.3)
Statistical analysis
  • Double-Blind Period: Vehicle Cream BID vs Double-Blind Period: Ruxolitinib Cream 1.5% BID · Cochran-Mantel-Haenszel · p = 0.091 · Odds ratio (or): 2.81 · 95% CI 0.83 to 9.47stratified by the stratification factor (face and/or neck Investigator's Global Assessment \[IGA\] score of 2 or 3 at screening).
  • Double-Blind Period: Vehicle Cream BID vs Double-Blind Period: Ruxolitinib Cream 1.5% BID · Response rate difference: 19.5 · 95% CI -0.5 to 39.6The 95% confidence interval was computed based on a large-sample normal approximation with continuity correction.
SecondaryPercentage of Participants Who Achieve an EASI75 of the Head and Neck Region at Weeks 2 and 8

The EASI scoring system examines 4 areas of the body (head/neck, trunk, upper limbs, and lower limbs) and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72; the severity strata are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. Specifically for the head and neck region, the EASI score ranges from 0 to 7.2 An EASI75 responder was defined as a participant achieving a 75% or greater improvement from Baseline in the EASI score for the head and neck.

Time frame:
Baseline; Weeks 2 and 8
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve an EASI75 of the Head and Neck Region at Weeks 2 and 8
percentage of participantsDouble-Blind Period: Vehicle Cream BIDDouble-Blind Period: Ruxolitinib Cream 1.5% BID
Week 216.7 (3.6 to 41.4)14.6 (6.1 to 27.8)
Week 835.3 (14.2 to 61.7)53.3 (37.9 to 68.3)
SecondaryPercentage of Participants Who Achieve an Overall EASI75 at Weeks 2, 4, and 8

The EASI scoring system examines 4 areas of the body (head/neck, trunk, upper limbs, and lower limbs) and weights them for participants of at least 8 years of age. Each of the 4 body regions is assessed separately for erythema (E), induration/papulation/edema (I), excoriations (Ex), and lichenification (l) on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 to 72; the severity strata are as follows: 0 = clear; 0.1 to 1.0 = almost clear; 1.1 to 7.0 = mild; 7.1 to 21.0 = moderate; 21.1 to 50.0 = severe; 50.1 to 72.0 = very severe. An EASI75 responder was defined as a participant achieving 75% or greater improvement from Baseline in EASI score.

Time frame:
Baseline; Weeks 2, 4, and 8
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve an Overall EASI75 at Weeks 2, 4, and 8
percentage of participantsDouble-Blind Period: Vehicle Cream BIDDouble-Blind Period: Ruxolitinib Cream 1.5% BID
Week 25.6 (0.1 to 27.3)10.4 (3.5 to 22.7)
Week 433.3 (13.3 to 59.0)29.2 (17.0 to 44.1)
Week 835.3 (14.2 to 61.7)33.3 (20.0 to 49.0)
SecondaryDouble-Blind Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

A TEAE was defined as any adverse event (AE) either reported for the first time or the worsening of a pre-existing event after the first application of the study drug. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug.

Time frame:
up to approximately 4 weeks plus 30 days
Reported as:
Count of participants · Participants
Double-Blind Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
ParticipantsDouble-Blind Period: Vehicle Cream BIDDouble-Blind Period: Ruxolitinib Cream 1.5% BID
Double-Blind Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)56
SecondaryOpen-Label Period: Number of Participants With Any TEAE

A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of the study drug. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug.

Time frame:
from first dose date in Open-Label Period (start of Week 5) until last follow-up visit (up to approximately 4 weeks plus 30 days)
Reported as:
Count of participants · Participants
Open-Label Period: Number of Participants With Any TEAE
ParticipantsOpen-Label Period: Vehicle Cream to Ruxolitinib Cream 1.5% BIDOpen-Label Period: Ruxolitinib Cream 1.5% BID
Open-Label Period: Number of Participants With Any TEAE49
SecondaryDouble-Blind Period: Number of Participants With Any Grade 3 or Higher TEAE

A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of the study drug. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. The severity of AEs was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (Grades 1 to 5). Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL). Grade 3: severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4: life-threatening consequences; urgent intervention indicated. Grade 5: death related to AE.

Time frame:
up to approximately 4 weeks plus 30 days
Reported as:
Count of participants · Participants
Double-Blind Period: Number of Participants With Any Grade 3 or Higher TEAE
ParticipantsDouble-Blind Period: Vehicle Cream BIDDouble-Blind Period: Ruxolitinib Cream 1.5% BID
Double-Blind Period: Number of Participants With Any Grade 3 or Higher TEAE01
SecondaryOpen-Label Period: Number of Participants With Any Grade 3 or Higher TEAE

A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first application of the study drug. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug.

Time frame:
from first dose date in Open-Label Period (start of Week 5) until last follow-up visit (up to approximately 4 weeks plus 30 days)
Reported as:
Count of participants · Participants
Open-Label Period: Number of Participants With Any Grade 3 or Higher TEAE
ParticipantsOpen-Label Period: Vehicle Cream to Ruxolitinib Cream 1.5% BIDOpen-Label Period: Ruxolitinib Cream 1.5% BID
Open-Label Period: Number of Participants With Any Grade 3 or Higher TEAE11

Adverse events

Collected over from the time of Informed Consent Form signing until at least 30 days after the last application of study drug (up to Week 8 + 30 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vehicle Cream BID0/23 (0%)0/23 (0%)2/23 (8.7%)
Ruxolitinib Cream 1.5% BID0/71 (0%)0/71 (0%)1/71 (1.4%)
Most frequent other events
Most frequent other events
EventVehicle Cream BIDRuxolitinib Cream 1.5% BID
Application site reactionGeneral disorders2/231/71

Baseline characteristics

Age, Continuous
Age, Continuous(years)Double-Blind Period: Vehicle Cream BIDDouble-Blind Period: Ruxolitinib Cream 1.5% BIDTotal
Mean41.0 ± 13.4437.9 ± 14.3738.8 ± 14.08
Sex: Female, Male
Sex: Female, Male(Participants)Double-Blind Period: Vehicle Cream BIDDouble-Blind Period: Ruxolitinib Cream 1.5% BIDTotal
Female164662
Male7815
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Double-Blind Period: Vehicle Cream BIDDouble-Blind Period: Ruxolitinib Cream 1.5% BIDTotal
Hispanic or Latino156
Not Hispanic or Latino224971
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Double-Blind Period: Vehicle Cream BIDDouble-Blind Period: Ruxolitinib Cream 1.5% BIDTotal
White/Caucasian112031
Black/African-American102434
Asian145
American-Indian/Alaska Native011
Black, Asian101
Captured as "Hispanic" in the Database011
Black and Phillipino011
Mexican011
Indian011
Mexican and Spanish011
08

Study locations

1 site
  • Science37
    Culver City, California 90230, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Aug 2023, 20 months.

Results were first posted in Aug 2024, 1 year after primary completion.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 20 months is above that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2021
First posted
Nov 19, 2021
StartActual
Nov 10, 2021
Primary completionActual
Aug 3, 2023
CompletionActual
Sep 29, 2023
Results first posted
Aug 15, 2024
Last update
Aug 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05127421
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Nov 19, 2021
Start date
Nov 10, 2021
Primary completion
Aug 3, 2023
Completion
Sep 29, 2023
Results posted
Aug 15, 2024
Last update
Aug 15, 2024

Study contacts

Haq Nawaz, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion